Pfizer Inc. (NYSE: PFE), Astellas Pharma Inc. (TSE: 4503) and Merck & Co. Inc. (NYSE: MRK) have gained a major U.S. Food and Drug Administration expansion for Padcev, or enfortumab vedotin-ejfv, combined with Keytruda, or pembrolizumab, as treatment before and after surgery for adults with muscle-invasive bladder cancer. The revised indication covers patients regardless of whether they are eligible for cisplatin, creating the first FDA-approved platinum-free perioperative regimen that spans the full adult muscle-invasive bladder cancer population.
The decision extends a November 2025 approval that had been limited to patients who were ineligible for or declined cisplatin-based chemotherapy. It was supported by the Phase 3 EV-304 trial, also known as KEYNOTE-B15, which directly compared perioperative Padcev plus Keytruda with neoadjuvant gemcitabine and cisplatin in patients considered fit enough to receive cisplatin.
This is more than a routine label expansion. The approval removes cisplatin eligibility as the main regulatory dividing line for the combination and gives oncology teams a single systemic treatment platform that can be considered across a broader range of patients undergoing curative-intent cystectomy. It also forces a more difficult clinical and economic question: whether a highly active antibody-drug conjugate and immunotherapy regimen should displace an established, less expensive chemotherapy backbone in patients who can still receive platinum treatment.
The label also permits Padcev to be used with intravenous Keytruda or Keytruda Qlex, the subcutaneous pembrolizumab formulation. That flexibility may help some treatment centres reduce infusion-chair pressure, although the overall pathway remains operationally demanding because treatment extends across neoadjuvant therapy, radical cystectomy and a prolonged adjuvant phase.
Why does the FDA expansion matter beyond adding another bladder cancer indication?
Muscle-invasive bladder cancer is an aggressive disease in which treatment is intended to cure, yet recurrence remains common even after removal of the bladder. Historically, cisplatin eligibility shaped the systemic treatment pathway. Patients healthy enough to tolerate cisplatin generally received neoadjuvant cisplatin-based chemotherapy before cystectomy, while many older or medically complex patients proceeded directly to surgery because kidney dysfunction, hearing loss, neuropathy or poor functional status made cisplatin unsuitable.
Padcev plus Keytruda had already changed the outlook for the cisplatin-ineligible group after EV-303, also known as KEYNOTE-905, showed that perioperative treatment improved event-free survival and overall survival compared with surgery alone. The new approval closes the remaining regulatory gap by extending the same combination into the cisplatin-eligible population, where it has now defeated active chemotherapy rather than a surgery-only control.
That distinction matters. A therapy that outperforms surgery alone addresses an unmet need, but a therapy that outperforms a recognised chemotherapy standard has a stronger claim to influence routine practice. EV-304 therefore shifts the discussion from whether Padcev plus Keytruda has activity in earlier-stage disease to whether its efficacy, safety, cost and treatment burden justify replacing cisplatin-based care for many patients.
The broad label does not require selection by PD-L1 expression or a Nectin-4 biomarker threshold. That simplifies prescribing and expands the addressable population, but it may also intensify pressure to identify which patients derive enough incremental benefit to justify the toxicity and expense of a long perioperative combination.
How convincing are EV-304 results against cisplatin-based neoadjuvant chemotherapy?
EV-304 enrolled more than 800 cisplatin-eligible patients with muscle-invasive bladder cancer who were candidates for radical cystectomy. Participants received either Padcev plus Keytruda before surgery followed by planned adjuvant treatment, or four cycles of neoadjuvant gemcitabine and cisplatin followed by surgery.
The combination reduced the risk of recurrence, progression or death by 47% compared with chemotherapy, producing a hazard ratio of 0.53. At two years, an estimated 79.4% of patients in the Padcev plus Keytruda group were event-free, compared with 66.2% in the gemcitabine and cisplatin group. Overall survival also favoured the combination, with a 35% reduction in the risk of death and a hazard ratio of 0.65.
The pathological complete response result adds clinical weight because it measures whether detectable invasive cancer remains in the removed bladder and lymph-node tissue. Padcev plus Keytruda produced a pathological complete response in 55.8% of patients, compared with 32.5% after gemcitabine and cisplatin. The improvement was not merely a radiographic signal before surgery; it was visible in the surgical specimen and accompanied by better event-free and overall survival.
The trial’s randomized design, active comparator and survival findings make the evidence unusually persuasive for a perioperative oncology approval. The benefits were also reported across major predefined subgroups, including PD-L1 status, clinical stage and Nectin-4 expression categories. However, subgroup analyses are not a substitute for dedicated prospective studies, particularly in smaller groups with variant histology or node-positive disease.
Longer follow-up remains important because many patients were still alive and event-free at the analysis cutoff. The durability of benefit, patterns of late recurrence and long-term consequences of treatment-related neuropathy will influence how confidently clinicians recommend the regimen to patients who might otherwise do well with chemotherapy and surgery.
Does a platinum-free regimen automatically become the preferred perioperative standard?
The expanded approval gives Padcev plus Keytruda a compelling efficacy position, but regulatory availability does not automatically settle treatment choice. Cisplatin-based chemotherapy is familiar, time-limited and supported by decades of clinical experience. Its toxicities are substantial, but many cancer centres have established protocols for hydration, renal monitoring, antiemetic support and surgical scheduling.
Padcev plus Keytruda replaces platinum exposure with a different risk profile rather than eliminating treatment burden. Enfortumab vedotin is an antibody-drug conjugate directed at Nectin-4 and delivers the microtubule-disrupting payload monomethyl auristatin E into target-expressing cells. Pembrolizumab blocks the PD-1 pathway to enhance antitumour immune activity. The biological rationale is strong, but the combination can produce serious skin reactions, peripheral neuropathy, hyperglycaemia, pneumonitis and immune-mediated complications.
Treatment duration is another differentiator. EV-304 planned nine cycles of Padcev and 17 cycles of pembrolizumab across the preoperative and postoperative periods. By comparison, neoadjuvant gemcitabine and cisplatin is completed before surgery. The longer pathway may improve systemic disease control, but it increases the number of appointments, monitoring requirements and opportunities for dose interruption.
Patient preference will therefore matter. Some patients may strongly favour avoiding cisplatin because of concerns about kidney injury, hearing loss or nausea. Others may prefer a shorter preoperative course and no planned year-long immunotherapy component. Shared decision-making will need to move beyond the simple question of cisplatin fitness and consider competing toxicities, treatment duration, employment, travel, caregiver support and the likelihood of completing adjuvant therapy.
What safety and treatment-completion issues could limit real-world adoption?
Grade 3 or higher adverse events from any cause occurred in 75.7% of patients receiving perioperative Padcev plus Keytruda in EV-304, compared with 67.2% of those receiving neoadjuvant chemotherapy. The difference does not erase the efficacy advantage, but it prevents the platinum-free label from being interpreted as a low-toxicity option.
Skin toxicity is one of the most important operational risks. Across muscle-invasive bladder cancer studies, skin reactions were reported in a majority of patients treated with Padcev and intravenous pembrolizumab, and serious cutaneous reactions can occur early. The Padcev label carries a boxed warning for severe and potentially fatal skin reactions, requiring rapid recognition, treatment interruption and permanent discontinuation in specified cases.
The effect on surgery is particularly relevant in a curative-intent setting. In the EV-304 safety population, some patients did not undergo surgery because of adverse reactions, while others experienced treatment-related surgical delays. Those numbers were relatively small, but any toxicity that prevents or postpones cystectomy carries different implications from toxicity in metastatic disease, where systemic treatment itself is the primary intervention.
Completion of postoperative therapy may prove even more challenging outside clinical trials. A substantial proportion of patients who underwent surgery in EV-304 did not start adjuvant Padcev, and adverse events accounted for many discontinuations before the adjuvant phase. Real-world patients may be older, frailer and less closely monitored than trial participants, potentially widening the gap between an approved regimen and the treatment actually delivered.
Hospitals will need clear multidisciplinary pathways connecting medical oncology, urologic surgery, dermatology, endocrinology and supportive care. The approval is commercially important, but its clinical value will depend on whether centres can identify toxicity early without disrupting surgery or abandoning treatment after only the neoadjuvant phase.
How does the approval alter competition with AstraZeneca’s Imfinzi regimen?
The U.S. perioperative muscle-invasive bladder cancer market is no longer a contest between chemotherapy and surgery alone. AstraZeneca’s Imfinzi, or durvalumab, was approved in March 2025 with neoadjuvant gemcitabine and cisplatin followed by adjuvant Imfinzi after surgery. That regimen improved event-free survival and overall survival in the Phase 3 NIAGARA trial and established immunotherapy around cystectomy for cisplatin-eligible patients.
Padcev plus Keytruda now offers a platinum-free alternative with strong results against gemcitabine and cisplatin. Cross-trial comparisons require caution because EV-304 and NIAGARA enrolled different populations, used different experimental regimens and were not designed to compare against each other. The hazard ratios may look favourable for Padcev plus Keytruda, but they cannot establish superiority over perioperative Imfinzi plus chemotherapy.
The practical competition will centre on treatment philosophy. One approach preserves cisplatin and adds checkpoint inhibition. The other replaces cisplatin with an antibody-drug conjugate while retaining checkpoint inhibition before and after surgery. Oncology teams may prefer the familiarity of chemotherapy for some patients, while choosing Padcev plus Keytruda for those seeking to avoid platinum or for whom the EV-304 efficacy profile appears especially persuasive.
Payers may encourage more explicit sequencing criteria because both perioperative strategies involve branded immunotherapy, and Padcev adds another high-cost biologic component. Comparative effectiveness studies, institutional pathways and real-world outcomes may become as influential as the labels themselves.
What does the broader label mean for Pfizer, Astellas Pharma and Merck investors?
For Pfizer, the approval is another test of whether the Seagen acquisition can generate durable oncology growth. Padcev is one of the clearest commercial assets inherited through that transaction, and expansion from advanced urothelial cancer into curative-intent muscle-invasive disease increases the number of patients who may receive the drug and extends treatment into an earlier stage.
Astellas Pharma has even greater direct exposure to Padcev as one of its strategic growth brands. The company reported strong Padcev sales growth in its latest fiscal year, driven by first-line metastatic uptake and early contribution from the cisplatin-ineligible muscle-invasive bladder cancer launch. The broader U.S. label provides another expansion lever, although revenue will depend on physician adoption, payer access and the proportion of patients completing postoperative treatment.
For Merck, the decision reinforces Keytruda’s role as a combination backbone across tumour stages and modalities. Pairing pembrolizumab with an antibody-drug conjugate in both advanced and potentially curable bladder cancer strengthens the franchise and supports Merck’s broader strategy of using Keytruda with targeted agents rather than relying only on chemotherapy combinations.
The immediate stock response was muted. Pfizer shares closed July 10 at $24.17, down about 0.3%, while Merck shares ended at $123.54, down about 1.2%. Astellas Pharma closed in Tokyo at ¥2,142, up about 0.2%, before the U.S. announcement. The limited reaction suggests that investors had largely anticipated approval after the positive EV-304 data and priority review, while Pfizer’s wider growth challenges and Merck’s much larger Keytruda franchise diluted the impact of a single indication.
Which evidence gaps will determine whether Padcev plus Keytruda dominates practice?
The next phase is not about proving that Padcev plus Keytruda works. EV-303 and EV-304 have already produced survival evidence across cisplatin-ineligible and cisplatin-eligible populations. The more consequential questions concern treatment selection, completion, value and long-term toxicity.
Clinicians will watch whether the regimen maintains its effectiveness in community practice, where patients may have more comorbidities and less intensive toxicity surveillance. They will also examine whether patients who receive only neoadjuvant therapy but cannot complete the adjuvant phase retain most of the survival benefit, a question that the approved schedule does not answer directly.
Payers and health systems will need to assess the cost of nine planned Padcev cycles, prolonged pembrolizumab therapy, toxicity management and surgery against the potential savings from preventing metastatic recurrence. A higher upfront treatment cost may be defensible if the regimen produces durable cures, but mature survival data and real-world health-economic evidence will be essential.
The FDA expansion gives Padcev plus Keytruda the broadest perioperative muscle-invasive bladder cancer label and a powerful clinical argument. Its ultimate position will depend on whether oncology teams can convert trial-level efficacy into routine, safely completed care without delaying cystectomy or exposing lower-risk patients to unnecessary treatment. The approval has removed cisplatin eligibility as a regulatory barrier, but it has made patient selection more complex rather than less important.
